Trader Hub

Author: traderhub8   |   Latest post: Fri, 20 May 2022, 9:29 AM


Singapore Exchange Limited – Taking Multi-asset Business to Next Level

Author:   |    Publish date:

  • SGX is focusing on building a multi-asset exchange, widening its partnerships and networks and growing its international presence.
  • Growth pipeline includes M&A targets that will augment its offerings, accelerating the growth of Scientific Beta and building an integrated forex marketplace to increase revenue contributions from the current 6%.
  • S$55mn – S$60mn capex set aside to modernise its system architecture, digitalise and invest in its foreign exchange and fixed-income businesses.
  • Maintain ACCUMULATE with higher TP of S$11.25, from S$11.01. Our TP is now pegged to its historical five-year mean of 23x FY21e PE vs. -1SD previously in view of its stronger growth prospects.

At its recent Analysts’ Day, SGX detailed its plan to strengthen its core businesses and invest in its next leg of growth.

The Positives

+ Focus on building multi-asset exchange. SGX remains committed to expanding its suite of products through strategic partnerships and new product development for newly-acquired businesses with the aim of serving clients end to end. Fixed Income, Currencies and Commodities (FICC) and Data Connectivity and Indices (DCI) made up 33% of its revenue in 1HFY21, up from 20% in FY15 (Figure 1).

FICC and DCI will remain its growth engines, providing opportunities from cross-selling and new client acquisitions to an enlarged trading network. The exchange will deploy proceeds from its recent bond issuance of S$380mn to scale up its presence in FICC and DCI.

+ Pipeline for growth includes acquisitions, accelerating growth of Scientific Beta and building an integrated forex marketplace. The bourse is seeking out M&As to build capabilities in newer segments. It will seek “fill the gap” deals that will enhance its end-to-end offerings to clients. Its recent acquisitions of Scientific Beta and BidFX is a case in point.

The acquisition of Scientific Beta, a smart beta firm in January 2020, for €186mn or S$280mn in cash is expected to be earnings-accretive in FY21e. Over 60 asset owners and asset managers use Scientific Beta’s indices to track or benchmark their smart beta investments. We estimate about 30% of these assets under replication were integrating ESG dimensions. We see the bourse relying on Scientific Beta to create new products to mitigate the loss of MSCI product volumes.

+ Healthy pipeline for rest of 2021. The bourse reports a healthy pipeline of potential listings across sectors and geographies. With market infrastructure and processes in place, it also sees the potential for increased secondary listings of unicorns from the US via its Nasdaq partnership.


Source: Phillip Capital Research - 16 Jun 2021

Share this
Labels: SGX

Related Stocks

Chart Stock Name Last Change Volume 
SGX 9.80 -0.12 (1.21%) 2,241,800 

  Be the first to like this.

I3 Messenger
Individual or Group chat with anyone on I3investor

148  265  182  583 

Top 10 Active Counters
 Sembcorp Marine 0.106+0.003 
 YZJ Fin Hldg 0.475+0.04 
 Jiutian Chemical 0.109-0.002 
 AA 0.014-0.003 
 Parkson Retail 0.0450.00 
 HSI 21400MBeC.. 0.058-0.017 
 Dyna-Mac 0.148+0.001 
 Genting Sing 0.78-0.01 
 HSI 18200MBeP.. 0.061+0.009 
 SingTel 2.65-0.02